-
公开(公告)号：US20190119383A1
公开(公告)日：2019-04-25
申请号：US16138417
申请日：2018-09-21
发明人： Peter BRUENKER , Rebecca CROASDALE-WOOD , Christian KLEIN , Juergen Michael SCHANZER , Kay-Gunnar STUBENRAUCH , Pablo UMANA , Martina GEIGER , Eric SULLIVAN , Jigar PATEL
摘要： The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
-
公开(公告)号：US20220357340A1
公开(公告)日：2022-11-10
申请号：US17806869
申请日：2022-06-14
发明人： Kevin BRADY , Gregor JORDAN , Sylvia ROTTACH , Martin SCHAEFER , Roland STAACK , Kay-Gunnar STUBENRAUCH
IPC分类号： G01N33/68 , G01N33/543
摘要： Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , tissue = C t m A b , tissue , det . C t i s sue , sample - C r e f m A b , tissue , det . C t i s sue , sample C r e f m A b , plasma . det . * C t m A b , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.=obtained by determining the concentration of the therapeutic antibody in a blood sample of the experimental animal directly prior to taking the tissue sample, CrefmAb,tissue,det.=obtained by determining the concentration of the inert reference antibody in the tissue sample of the experimental animal, CrefmAb,plasma,det.=obtained by determining the concentration of an inert reference antibody in the blood sample of the experimental animal directly prior to taking the tissue sample, Ctissue,sampie=obtained by determining the tissue concentration in the tissue sample, whereby the inert reference antibody does not penetrate into said tissue, whereby the inert reference antibody is administered 2 to 10 minutes prior to obtaining the tissue and blood sample.
-
公开(公告)号：US20220275087A1
公开(公告)日：2022-09-01
申请号：US17541021
申请日：2021-12-02
发明人： Peter BRUENKER , Rebecca CROASDALE-WOOD , Christian KLEIN , Juergen Michael SCHANZER , Kay-Gunnar STUBENRAUCH , Pablo UMANA , Martina GEIGER , Eric SULLIVAN , Jigar PATEL
摘要： The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
-
公开(公告)号：US20200093860A1
公开(公告)日：2020-03-26
申请号：US16576546
申请日：2019-09-19
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , C07K14/71 , C07K16/28 , C07K16/30 , C07K16/40
摘要： The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain. The invention also provides the production and use of T cells in a method for the treatment of particular diseases in conjunction with tumor-specific antibodies as well as pharmaceutical compositions/medicaments comprising T cells and/or therapeutic antibodies, wherein T cells are to be administered in combination with therapeutic-tumor targeting antibody/antibodies comprising a mutated Fc domain with reduced Fc receptor binding.
-
公开(公告)号：US20190170765A1
公开(公告)日：2019-06-06
申请号：US16107801
申请日：2018-08-21
IPC分类号： G01N33/68 , G01N33/543
摘要： The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.
-
公开(公告)号：US20230131782A1
公开(公告)日：2023-04-27
申请号：US17810287
申请日：2022-06-30
摘要： Herein is reported a method for determining the epitope of an antibody specifically binding to a therapeutic antibody comprising the steps of a) incubating a sample, which comprises serum and the antibody specifically binding to a therapeutic antibody, separately with i) at least a Fab fragment of the therapeutic antibody, and ii) at least a Fab fragments of the therapeutic antibody in which the HVRs forming a paratope have been replaced with germline sequences, and detecting the binding or non-binding of the antibody specifically binding to a therapeutic antibody to the at least a Fab fragment in any of i) to ii), and b) determining the epitope of the antibody specifically binding to a therapeutic antibody to be in the at least one HVR that has been replaced in ii) if binding is detected in i) and non-binding is detected in ii).
-
公开(公告)号：US20230119537A1
公开(公告)日：2023-04-20
申请号：US17843565
申请日：2022-06-17
发明人： Peter BRUENKER , Rebecca CROASDALE-WOOD , Christian KLEIN , Juergen Michael SCHANZER , Kay-Gunnar STUBENRAUCH , Pablo UMANA , Martina GEIGER , Eric SULLIVAN , Jigar PATEL
摘要： The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
-
公开(公告)号：US20200309786A1
公开(公告)日：2020-10-01
申请号：US16783623
申请日：2020-02-06
发明人： Janis BROCKHAUS , Astrid REISER , Mirko RITTER , Kay-Gunnar STUBENRAUCH , Rudolf VOGEL , Markus ZADAK
IPC分类号： G01N33/68 , G01N33/543 , C07K16/18
摘要： The present invention relates to in vitro methods for determining the presence or absence of an anti-drug antibody (ADA) or drug/ADA immunecomplexes in a minipig sample. The invention further relates to antibodies specifically binding to minipig IgG that are applicable in the methods of the invention.
-
公开(公告)号：US20230390338A1
公开(公告)日：2023-12-07
申请号：US18312339
申请日：2023-05-04
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/30 , C07K16/40
CPC分类号： A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K16/283 , C07K16/2887 , C07K16/3007 , C07K16/40 , A61K38/00
摘要： The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain. The invention also provides the production and use of T cells in a method for the treatment of particular diseases in conjunction with tumor-specific antibodies as well as pharmaceutical compositions/medicaments comprising T cells and/or therapeutic antibodies, wherein T cells are to be administered in combination with therapeutic-tumor targeting antibody/antibodies comprising a mutated Fc domain with reduced Fc receptor binding.
-
公开(公告)号：US20210055304A1
公开(公告)日：2021-02-25
申请号：US16945730
申请日：2020-07-31
IPC分类号： G01N33/68 , G01N33/543
摘要： Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.019 秒)
